Metastatic adenocarcinomas of unknown primary site: Prognostic variables and treatment results Journal Article

  


Authors: Kambhu, S. A.; Kelsen, D. P.; Fiore, J.; Niedzwiecki, D.; Chapman, D.; Vinciguerra, V.; Rosenbluth, R.
Article Title: Metastatic adenocarcinomas of unknown primary site: Prognostic variables and treatment results
Abstract: As part of a Phase II chemotherapy trial using mitomycin-C, adriamycin, and vindesine, 57 patients with adenocarcinoma of unknown primary site were assessed for prognostic variables predictive of response and survival. They were also evaluated for response and toxicity, usefulness of screening techniques, and eventual definition of primary site and pattern of progression. Only gender predicted response, with women being more likely to respond than men. Visceral metastases below the diaphragm, or the presence of liver metastases, predicted poor survival. Responding patients were highly likely to relapse first at sites of initial disease. Hemolytic-uremic syndrome was the most severe toxicity; other side effects were moderate. The response rate was 30% (three complete responders), which is similar to other current regimens. This study suggests that patients with better prognosis characteristics of single site of disease and without intraabdominal tumor may benefit from a policy of expectant observation after local countrol has been established. Patients with multiple sites of disease and/or intraabdominal tumor are appropriate candidates for investigational chemotherapy.
Keywords: major clinical study; doxorubicin; adenocarcinoma; metastasis; phase 2 clinical trial; age; mitomycin c; vindesine; sex difference; hemolytic uremic syndrome; human; male; female; article
Journal Title: American Journal of Clinical Oncology
Volume: 13
Issue: 1
ISSN: 0277-3732
Publisher: Lippincott Williams & Wilkins  
Date Published: 1990-02-01
Start Page: 55
End Page: 60
Language: English
DOI: 10.1097/00000421-199002000-00015
PUBMED: 2106257
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025212148&doi=10.1097%2f00000421-199002000-00015&partnerID=40&md5=abd869273bb60122c3f94088bdf95df4
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. John J Fiore
    14 Fiore
  2. David P Kelsen
    537 Kelsen
  3. Donna Niedzwiecki
    61 Niedzwiecki
  4. Douglass S. Chapman
    35 Chapman
Related MSK Work